Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenethylamine SCHEMBL4960273 | 0.88 | NR4A2 (0.40) | RAB9ANPC1L3MBTL1NR4A2CYP1A2 | |
| SCHEMBL4960271 | 0.86 | KMT2A (0.53) | RAB9ANPC1L3MBTL1NR4A2CYP1A2 | |
| SCHEMBL27518661 | 0.81 | USP5 (0.47) | RAB9ANPC1L3MBTL1NR4A2CYP1A2 | |
| Phenethylamine SCHEMBL6778632 | 0.81 | CYP2C19 (0.44) | RAB9ANPC1CYP1A2FFAR1SMN1; SMN2 | |
| SCHEMBL4962692 | 0.80 | NPC1 (0.45) | RAB9ANPC1SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL23583035 | 0.77 | NR1H4 (0.54) | L3MBTL1FFAR1LMNAALDH1A1NR1H4 | |
| SCHEMBL9765140 | 0.76 | L3MBTL1 (0.69) | RAB9ANPC1L3MBTL1NR4A2CYP1A2 | |
| SCHEMBL15522680 | 0.76 | BRS3 (0.51) | RAB9ANPC1ALDH1A1POLBMAPT | |
| Phenethylamine SCHEMBL27518659 | 0.75 | RAB9A (0.48) | RAB9ANPC1L3MBTL1NR4A2CYP1A2 | |
| Hydrochloric Acid SCHEMBL10463257 | 0.75 | L3MBTL1 (0.67) | RAB9ANPC1L3MBTL1NR4A2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401816-B1 | PROCESS FOR THE PRODUCTION OF THE PIPERIDINE DERIVATIVE FEXOFENADINE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-02-13 | — | — | EP | disclosed |
| US-7235665-B2 | Process for the production of piperidine derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-26 | — | — | US | disclosed |
| CN-1229347-C | Process for preparing piperidine derivative fexofenadine | AVENTIS PHARMA GMBH (DE) | 2005-11-30 | — | — | CN | disclosed |
| US-20040198983-A1 | Process for the production of piperidine derivatives | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| CN-1516689-A | Process for production of piperidine derivative fexofenadine | ������ҽҩ�¹�����˾ | 2004-07-28 | — | — | CN | disclosed |
| US-6743941-B2 | INCLUDING FEXOFENADINE, USING THE CLAIMED CHEMICAL INTERMEDIATE, P-(2-CARBOXYETHYLCARBONYL)-ALPHA,ALPHA-DIMETHYLPHENYLACETIC ACID, ALKYL ESTER | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-01 | — | — | US | disclosed |
| EP-1401816-A1 | PROCESS FOR THE PRODUCTION OF THE PIPERIDINE DERIVATIVE FEXOFENADINE | Aventis Pharma Deutschland GmbH (DE) | 2004-03-31 | — | — | EP | disclosed |
| US-20030105329-A1 | Process for the production of piperidine derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-06-05 | — | — | US | disclosed |
| WO-2002102776-A1 | PROCESS FOR THE PRODUCTION OF THE PIPERIDINE DERIVATIVE FEXOFENADINE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105329-A1 | Process for the production of piperidine derivatives | HRH2, HRH1, HRH4 | RAB9A 1695/4885NPC1 3730/4885L3MBTL1 4881/4885 |
| US-20040198983-A1 | Process for the production of piperidine derivatives | HRH2, HRH1, HRH4 | RAB9A 1695/4885NPC1 3730/4885L3MBTL1 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.